Friday, October 2
Leave a little sharper than you arrived.
News, calculators, learning modules, conference recaps, and daily puzzles. Pick any one, and you’re a little further along than you were.
Today’s puzzle
Today's News
Daraxonrasib earns FDA approval for metastatic pancreatic cancer, nearly doubling survival
After decades of failed attempts to drug the "undruggable" KRAS protein, daraxonrasib (Rasonque) has received FDA approval for metastatic pancreatic cancer — and the data are stunning. In the phase 3 RASolute 302 trial, patients lived a median of 13.2 months on the daily pill vs. 6.7 months on chemotherapy. With 79 RAS-targeting drugs now in 238 trials worldwide, this is just the beginning.
FDA approves tavapadon (Juvmo), a first-in-class Parkinson's drug targeting D1/D5 receptors
FDA-approved rusfertide offers polycythemia vera patients a path away from phlebotomy
Next-gen obesity drugs race ahead: Survodutide trails the pack, while retatrutide and combo therapy push weight loss to new heights
Everything on Curie.MD
NeurologyPlay & LearnLearn what’s new in your field, a few minutes at a time.Start learningNeurologyConferencesEvery major conference, filtered to what matters for your practice.See the calendarCardiologyCalculatorsEnter the case once. See every relevant score, side by side.Open a calculatorAll fieldsGamesThree new clinical puzzles every morning.Play today
Get Curie’s Weekly Dose
What changed in clinical practice, policy, and coverage, and what it means for your patients.
Subscribe free Free. Weekly. Unsubscribe anytime.